Boston, MA (PRWEB) April 29, 2014
The National Patient Safety Foundation (NPSF), a central voice for patient safety since 1997, is pleased to announce that Mallinckrodt Pharmaceuticals has joined the NPSF Patient Safety Coalition. Mallinckrodt recently acquired Cadence Pharmaceuticals and its hospital-based pain product, and is a leading global specialty pharmaceuticals company.
“Mallinckrodt is committed to the safety of patients, including those in the hospital setting, and the safe use of our broad portfolio of specialty pharmaceutical products,” said Hugh O’Neill, senior vice president and president, U.S. Specialty Pharmaceuticals, Mallinckrodt. “Joining the NPSF Patient Safety Coalition strengthens that commitment by increasing our exposure to safety science and best practices.”
The NPSF Patient Safety Coalition was created to align stakeholders from across the continuum of care in a unifying mission to make health care safer for all. Membership is open to solutions providers working to address patient safety challenges, professional associations, advocacy organizations, and other entities. Joining the Coalition provides unique opportunities for networking, learning, and knowledge sharing through quarterly conference calls, an annual member meeting, and periodic webinars.
“Members of the NPSF Patient Safety Coalition share our goal of making health care safer across the continuum,” said Tejal K. Gandhi, MD, MPH, CPPS, president of NPSF. “We are very pleased to welcome Mallinckrodt Pharmaceuticals as a new member, and we look forward to working with them to share knowledge and promote innovations in the field.”
For more information about the NPSF Patient Safety Coalition and how to join, contact David Coletta, senior vice president, at dcoletta(at)npsf(dot)org.
About the National Patient Safety Foundation
The National Patient Safety Foundation’s vision is to create a world where patients and those who care for them are free from harm. A central voice for patient safety since 1997, NPSF partners with patients and families, the health care community, and key stakeholders to advance patient safety and health care workforce safety and disseminate strategies to prevent harm. NPSF is an independent, not-for-profit 501(c)(3) organization. To learn more about the Foundation’s work, visit http://www.npsf.org.
Mallinckrodt is a global specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide and a commercial presence in roughly 65 countries. The company's fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit http://www.mallinckrodt.com.